Description

Preductal MR (trimetazidine) coated tablets 35 mg. №60

Ingredients

Active ingredient: Trimetazidine 35 mg

Dosage

Dosage: The usual dose is 1 tablet twice a day, preferably taken with meals.

Indications

Indicated for: Symptomatic treatment of chronic stable angina pectoris.

Contraindications

Do not use if: Hypersensitivity to trimetazidine or any other component of the product.

Directions

Directions for use: Swallow the tablet whole with a sufficient amount of water. Do not crush or chew the tablet.

Scientific Evidence

Trimetazidine, the active ingredient in Preductal MR, is known for its unique mechanism of action in the treatment of angina. It acts by shifting myocardial metabolism from fatty acid oxidation towards glucose utilization, thereby improving myocardial efficiency and reducing the oxygen consumption of the heart muscle. Several studies have demonstrated the efficacy of trimetazidine in improving exercise capacity, reducing angina symptoms, and enhancing quality of life in patients with stable angina.

Additional Information

It is important to note that Preductal MR should be used as part of a comprehensive treatment plan for angina, including lifestyle modifications and other medications as prescribed by a healthcare provider. Regular follow-up with a healthcare professional is essential to monitor the effectiveness of the treatment and adjust the dosage if needed.

Pharmacological Effects

Trimetazidine’s pharmacological action involves the optimization of cellular metabolism in ischemic conditions, leading to improved cardiac function and reduced ischemic damage. By modulating cellular energy pathways, trimetazidine helps maintain the balance between oxygen supply and demand in the heart muscle, making it a valuable adjunct in the management of angina.

Clinical Trials and Comparative Effectiveness

Clinical trials have shown that trimetazidine, such as in Preductal MR tablets, is effective in reducing angina symptoms and improving exercise tolerance in patients with stable angina. Compared to other anti-anginal agents, trimetazidine offers a unique mechanism of action with minimal hemodynamic effects, making it a well-tolerated option for long-term angina management.

Overall, the scientific evidence supports the use of Preductal MR (trimetazidine) coated tablets 35 mg in the symptomatic treatment of chronic stable angina pectoris, highlighting its role as a valuable therapeutic option in the management of this cardiovascular condition.